Proctitis Clinical Trials

Find Proctitis Clinical Trials Near You

Intestinal Microbiome Profiles in Women With Gynecological Tumors and Pelvic Toxicity Secondary to Radiotherapy and Chemotherapy: Comparison With Controls and Effect of Rectal Ozone Treatment.

Status: Recruiting
Location: See all (2) locations...
Study Type: Observational
SUMMARY

Patients treated for gynecological tumors with radiotherapy (RT) and/or chemotherapy (CT) frequently develop pelvic toxicity (TPIRQT), a condition that can become persistent, progressive, and refractory to standard treatments. This toxicity, affecting the rectum (proctitis), bladder (cystitis), and vagina (mucositis), severely deteriorates quality of life. Standard options for refractory cases are limited; at our center, rectal ozone therapy is used with high rates of symptomatic improvement (66-75%). Emerging evidence suggests a link between gut microbiota and the development of TPIRQT. However, it is unknown how rectal ozone therapy may influence the gut microbiome or if this modulation is part of its therapeutic mechanism. This prospective observational study will investigate the potential relationship between gut microbiome profiles (composition and diversity), the presence and severity of TPIRQT, and the response to rectal ozone therapy.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult women (\>=18 years).

• Diagnosed with gynecological tumors (any location and stage).

• Previously treated with radiotherapy and/or chemotherapy.

• Must accept and sign the specific informed consent for this study.

• Additional Inclusion Criteria for inclusion in the TPIRQT Group (Cases):

• Must present chronic TPIRQT with \>= 3 months of duration after habitual symptomatic treatment.

• Must have a toxicity Grade of 2 (moderate symptoms, limiting instrumental ADL) or higher, according to the CTCAE v.5.0 scale.

Locations
Other Locations
Spain
Hospital Universitario de Gran Canaria Dr. Negrín, (FIISC)
RECRUITING
Las Palmas De Gran Canaria
Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias - Universidad de La Laguna
RECRUITING
San Cristóbal De La Laguna
Contact Information
Primary
Bernardino Clavo, MD, PhD
bernardinoclavo@gmail.com
34928449278
Backup
Francisco Rodríguez-Esparragón, BSc, PhD
afrodesp@gmail.com
34928449288
Time Frame
Start Date: 2026-01-15
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 38
Treatments
TPIRQT Group (Cases)
Patients with gynecological tumors treated with RT and/or CT who develop chronic pelvic toxicity (TPIRQT) and are referred for compassionate-use rectal ozone therapy at the Chronic Pain Unit. Samples and data will be collected before and after ozone therapy
Control Group
pelvic toxicity (TPIRQT). This group will be matched by age (± 5 years) and primary tumor location. Samples and data will be collected once during a follow-up visit.
Related Therapeutic Areas
Sponsors
Collaborators: Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna, Fundación Canaria Instituto de Investigación Sanitaria de Canarias, Complejo Hospitalario Universitario Insular Materno Infantil, Centers for International Business Education and Research, Hospital Universitario de Gran Canaria Doctor Negrín
Leads: Bernardino Clavo, MD, PhD

This content was sourced from clinicaltrials.gov